Bugs, Drugs, & Beyond: Translational Approaches to the Microbiome
Bugs, Drugs, & Beyond: Translational Approaches to the Microbiome
Quadrus Conference Center & Catering , 2400 Sand Hill Rd. , , CA 94025
September 12, 2017 from 12:00 PM to 18:30 PM (PST)
$10 - $35
Join the Janssen Human Microbiome Institute, JLABS @ SSF, Stanford Medicine, and Seventure for the 2017 West Coast Microbiome Forum, a 2-day event exploring key aspects of microbiome research. **Note - There is separate registration for each day.
September 11: Bioinformatics for the Microbiome, hosted by Stanford Medicine. Details/Register with Stanford here (Link will redirect you to a non-J&J Innovation website)
September 12: Bugs, Drugs & Beyond: Translational Approaches to the Mircrobiome, hosted by JHMI and JLABS.
Bugs, Drugs & Beyond: Translational Approaches will explore the ways in which innovators from San Francisco and beyond are harnessing the human microbiome and advancing novel therapeutics, diagnostics and other health products. During this event, we'll hear from entrepreneurs, academics, investors, and biotech and pharma companies about a variety of product development approaches and the organizations pursuing them.
Interactive sessions will highlight:
- Challenges in advancing to market, from IP protection to commercialization
- Potential solutions and pathways currently being pursued across the field
- Opportunities for collaboration
The Bugs, Drugs & Beyond Qu ickFire Challenge:
Are you a game-changing early-stage microbiome company? The Bugs, Drugs & Beyond QuickFire Challenge is officially open! We encourage innovators with promising ideas or research with the potential to impact patients to apply now. The winner will be awarded a customized package of support from the JHMI and JLABS, and will be announced at the event of the event on September 12. Applications for the Bugs, Drugs, & Beyond QuickFire Challenge will remain open until July 14, 2017. Apply online today!
Miguel Barbosa | Chief Scientific Officer -Microbiome, Assembly Biosciences read bio»
Colleen Cutcliffe | CEO, Whole Biome Inc. read bio»
Dirk Gevers | Global Head, Janssen Human Microbiome Institute, Janssen R&D read bio»
Denise Kelly | Investment Advisor, Seventure read bio»
Justin Sonnenburg | Principal Investigator, Stanford University read bio»
Lihi Segal | CEO, DayTwo read bio»
[Moderator] Stephanie Roberston | Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation read bio»
Gallery Walk Participants:
10:00am | Registration
10:15am | The Microbiome: A New Paradigm for Health Solutions
10:30am | Insights from the Front Lines of Microbiome Innovation
11:00am | QuickFire Challenge, Part I
12:00pm | Lunch and Gallery Walk
1:15pm | Balancing Blood Sugar Levels by Harnessing the Gut Microbiome
1:35pm | Panel Discussion: From Validation to Regulation: Breaking Down Barriers to Microbiome Progress
2:35pm | QuickFire Challenge, Part II
3:35pm | Networking Reception and QuickFire Challenge Winner Announced
4:50pm | Program Close
$40 | General Public
$20 | Student/Academic
$45 | At the door
Miguel Barbosa | Chief Scientific Officer -Microbiome, Assembly Biosciences
Dr. Barbosa has more than two decades of experience leading drug discovery and development programs at major pharmaceutical and biotechnology companies. Until 2015, Dr. Barbosa was Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, where he oversaw immunology R&D and new program initiatives, including establishing the foundation for, and then leading, Johnson & Johnson's new microbiome enterprise. Earlier in his career, Dr. Barbosa held positions of increasing responsibility managing new drug R&D programs at prominent biopharmaceutical firms, including Centocor, Signal Pharmaceuticals, TRL USA, Chugai Biopharma and Mirna Therapeutics. Dr. Barbosa received a BS degree from the University of California, Davis and a PhD from the University of California, Los Angeles. He completed a post-doctoral fellowship at the National Cancer Institute..
Colleen Cutcliffe | CEO and Co-founder, Whole Biome, Inc.
Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome Inc. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Whole Biome, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College..
Dirk Gevers | Global Head, Janssen Human Microbiome Institute, Janssen R&D
Dirk Gevers, Ph.D., is Global Head of the Janssen Human Microbiome Institute (JHMI), where he leads efforts to expand scientific understanding and capabilities in this emerging area of science. Previously, Dirk was Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard, serving as a scientific liaison among various organizational components, including the institute's data generation platforms and both clinical and analytical collaborators on microbiome-related projects. Dirk's research included the characterization of the microbial imbalance associated with diseases such as Crohn's disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health Human Microbiome Project, holding a leading role in the Data Analysis Working Group. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and the Massachusetts Institute of Technology in bioinformatics, comparative and evolutionary genome analysis and microbial ecology.
Denise Kelly | Investment Advisor, Seventure
Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field. Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome. Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.
Justin Sonnenburg | Principal Investigator, Stanford University
Justin Sonnenburg conducted his Ph.D. in Biomedical Sciences at the University of California, San Diego. His graduate studies in the laboratory of Ajit Varki focused on the biological roles of glycosylation, performing comparative studies on sialic acids and their receptors in humans and great apes, to shed light on the molecular evolutionary history of humans. In 2003, Justin moved to Washington University in Saint Louis, Missouri to join the laboratory of Jeffrey Gordon, where he applied his background in glycobiology to study host-microbial interactions within the gastrointestinal tract. During his post-doc, Justin investigated model microbial communities living within the gut of gnotobiotic mice to define the basic principles that govern interactions within the microbiota and between the microbiota and the host. In 2008, Justin moved back to California and is currently Assistant Professor in the Department of Microbiology and Immunology at the Stanford University School of Medicine. In 2009 Justin was the recipient of an NIH Director's New Innovator Award. In 2011 he received the Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award. He and Erica Sonnenburg, PhD, are the authors of the forthcoming book The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long Term Health.
The Sonnenburg lab is currently focused on understanding basic principles that govern interactions within the intestinal microbiota and between the microbiota and the host. To pursue these aims, his lab colonizes germ-free (gnotobiotic) mice with simplified, model microbial communities, applies systems approaches (e.g. functional genomics), and uses genetic tools for the host and microbes to gain mechanistic insight into emergent properties of the host-microbial super-organism.
Lihi Segal | CEO, DayTwo
Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.
For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.
Stephanie Robertson | Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation
Stephanie is part of the New Ventures Team at J&J Innovation. As part of her role at J&J Innovation, she works closely with the Janssen Human Microbiome Institute and with J&J Consumer Emerging Sciences to create collaborations with academic experts and biotech companies with a goal of accelerating the translation of microbiome research into breakthrough solutions that promote health. Previously Stephanie was at the University of California, San Francisco UCSF where she helped to establish and grow translational efforts on campus including her role as Program Director for the Sandler Center for Drug Discovery, and for the Grand Multiple Myeloma Translational Initiative. She later took on the role of Director, Strategic Alliances where she led business development and alliance management activities for the campus. Prior to joining UCSF, Stephanie worked for over a decade at Exelixis, Inc, where she held diverse leadership roles including leading a computational biology team and acting as scientific project leader for numerous drug discovery programs in cancer, cardiovascular disease and metabolism as well as managing early oncology clinical programs and alliances for several programmatic collaborations with large pharma..
Stephanie earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.
Quadrus Conference Center
Menlo Park, CA
There is ample parking available and highlighed on Map 3 below; there is a path that will lead you up to the 2400 building